Category Specific RSS

ldx

Lumos FDA appeal rejected yet again

One of the punching bags of the ASX, Lumos Diagnostics (ASX: LDX),  which develops diagnostics for healthcare professionals to more…

3 years ago

False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits

While small cap shareholders have become accustomed to major share price gains once a medtech or biotech receives FDA approval…

3 years ago

Lumos Diagnostics receives regulatory approval for rapid test in Brazil

Rapid antigen tests (or lack thereof) have dominated the headlines for months now. Turning your kitchen counter into a mini…

3 years ago

RATs – The ASX-listed companies manufacturing Rapid Antigen Tests that you cannot buy

With 'Rapid Antigen Test' having only taken several days to likely be one of the most commonly used words of…

4 years ago

Lumos receives first orders from Canada for rapid COVID test kits following regulatory approval

Having secured approval from regulators in Canada last month, Lumos Diagnostics (ASX: LDX) is set to dispatch the first orders…

4 years ago

IPO Watch: Lumos to accelerate decentralised healthcare diagnostics with $187m float

With ever increasing bodies of medical research and demand for early disease detection climbing, it's high time that we rethink…

4 years ago